Phathom Pharmaceuticals, Inc. (PHAT) — 10-Q Filings
All 10-Q filings from Phathom Pharmaceuticals, Inc.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — Apr 30, 2026
-
Phathom's Revenue Soars 359% Amidst Deepening Losses
— Oct 30, 2025 Risk: high
Phathom Pharmaceuticals, Inc. (PHAT) reported a significant increase in product revenue for the nine months ended September 30, 2025, reaching $117.5 million, a -
Phathom's Q2 Loss Widens Amid Rising Commercialization Costs
— Aug 7, 2025 Risk: high
Phathom Pharmaceuticals, Inc. reported a net loss of $60.3 million for the three months ended June 30, 2025, a significant increase from the $49.8 million net l -
Phathom Pharma Files Q1 2025 10-Q
— May 1, 2025 Risk: medium
Phathom Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance, including research and dev -
Phathom Pharmaceuticals Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
Phathom Pharmaceuticals, Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company's primary focus is on its product Voquezna. Financi -
Phathom Pharmaceuticals Files Q2 2024 10-Q
— Aug 8, 2024 Risk: medium
Phathom Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company's financial activities include a Takeda License Agreement and vari -
Phathom Pharmaceuticals Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: medium
Phathom Pharmaceuticals, Inc. (PHAT) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Phathom Pharmaceuticals, Inc. filed a 10-Q report for the peri
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX